Innovative Molecular Diagnostics for Improved Patient Outcomes
Transforming Lung Cancer Care.
The only comprehensive solution for the molecular management of early stage non-small cell lung cancer
Molecular Prognostic & Predictive Assay for Early Stage Lung Cancer
The CLIA-certified Razor Genomics Molecular Prognostic Assay is helping to lead a revolution in the precision management of the world’s deadliest cancer. The assay, backed by the most extensive, blinded, independent validation studies published for any molecular prognostic in lung cancer, 1-4 provides patients who have undergone resection of non-squamous, non-small cell lung cancer and their doctors with the most accurate prognostic designation available into high-, intermediate- or low-risk of death within 5 years after operation.
Early data have also indicated that disease-free survival was improved in high- and intermediate-risk patients who underwent adjuvant, post-operative chemotherapy.4
Contact our CLIA-certified laboratory for more information on how to obtain the assay: (844) 662-6298*
References
1. Kratz et al. Lancet 2012;379:823
2. Kratz et al. JAMA 2012;308:1629
3. Woodard et al. Clin Lung Cancer 2014:15:426
4. Woodard et al. Clin Lung Cancer 2018: 19:58
*The Razor 14-Gene Lung Cancer Assay, provided only by Razor’s CLIA-certified laboratory, under the brand name RiskReveal. The RiskReveal list price is $5000. Razor Genomics will bill insurance on behalf of the patient and has a financial assistance program for patients that qualify. More information about the financial assistance program is available at www.razorgenomics.com.
Breakthrough in the effective management and treatment of cancer.
Contact us.
Razor Genomics provides the only validated solution for the molecular management of early stage non-small cell lung cancer.
(844) 662-6298
111 10th Avenue South, Suite 102, Room 123, Nashville, TN, 37203